Effect of vitamin D supplementation on serum hepcidin levels in non-diabetic chronic kidney disease patients

被引:1
|
作者
Kamboj, Kajal [1 ]
Yadav, Ashok K. [2 ,6 ]
Kumar, Vivek [1 ]
Jha, Vivekanand [3 ,4 ,5 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh, India
[3] George Inst Global Hlth, UNSW, New Delhi, India
[4] Imperial Coll London, Sch Publ Hlth, London, England
[5] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, Karnataka, India
[6] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India
关键词
Cholecalciferol; chronic kidney disease; hepcidin; IRON-METABOLISM; D DEFICIENCY; INDUCTION; ANEMIA;
D O I
10.4103/ijn.ijn_28_23
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Vitamin D deficiency and anemia frequently coexist. Moreover, vitamin D deficiency is found to play a role in chronic kidney disease (CKD)-associated anemia. We investigated the effect of cholecalciferol on serum hepcidin levels in vitamin D-deficient, non-diabetic individuals with CKD in a randomized, double-blind, placebo-controlled trial.Methods: This study was performed on stored samples of our previously published randomized, double-blind, placebo-controlled trial of cholecalciferol supplementation in non-diabetic patients with stage III-IV CKD and vitamin D deficiency. Stable patients of either sex, aged 18-70 years, with non-diabetic stage III-IV CKD (estimated glomerular filtration rate between 15 and 60 ml/min/1.73 m(2)), and having serum 25-hydroxyvitamin D-3 [25(OH) D] levels <= 20 ng/ml were included. Participants received either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and at eight weeks. Follow-up was done at 16 weeks. Serum hepcidin levels were analyzed at baseline and at 16 weeks.Results: A total of 120 CKD patients were enrolled. Serum 25(OH) D levels were similar in the placebo and cholecalciferol groups at baseline (13.21 +/- 4.78 ng/ml and 13.40 +/- 4.42 ng/ml; P = 0.88). After 16 weeks, the serum 25(OH) D levels were found to be increased in the cholecalciferol group but not in the placebo group (between-group difference in mean change 23.40 ng/ml; 95% CI: 19.76 to 27.06; P < 0.001). Serum hepcidin levels were similar at baseline (median [IQR]: 33.6 [8.6-77.8] ng/ml vs. 24.6 [9.3-70.7] ng/ml, P = 0.903) and did not vary between groups at 16 weeks (median [IQR]: 41.5 [10.9-75.0] ng/ml vs. 34.8 [12.3-63.75] ng/ml, P = 0.703).Conclusion: Our study provides preliminary data based on which a larger adequately powered clinical trial can be conducted to conclusively assess the impact of vitamin D supplementation on hepcidin levels and anemia in patients with CKD and vitamin D deficiency.
引用
收藏
页码:444 / +
页数:6
相关论文
共 50 条
  • [31] Relationship Between Serum Uromodulin as a Marker of Kidney Damage and Metabolic Status in Patients with Chronic Kidney Disease of Non-Diabetic Etiology
    Zeravica, Radmila
    Ilincic, Branislava
    Buric, Dragan
    Jakovljevic, Ana
    Crnobrnja, Veljko
    Ilic, Dalibor
    Papuga, Marija Vukmirovic
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [32] Serum Hepcidin as an Inflammatory Marker in Chronic Kidney Disease
    Roy, Jyothi Elizabeth
    Shanthi, B.
    Selvi, V. S. Kalai
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2020, 32 (12) : 40 - 45
  • [33] Non-Diabetic Chronic Kidney Disease Influences Retinal Microvasculature
    Baumann, Marcus
    Schwarz, Sonja
    Kotliar, Konstantin
    von Eynatten, Maximilian
    Trucksaess, Arno Schmidt
    Burkhardt, Klaus
    Lutz, Jens
    Heemann, Uwe
    Lanzl, Ines
    KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (06) : 428 - 433
  • [34] Correction of Vitamin D Levels in Patients with Diagnosed Chronic Kidney Disease
    Karakulova, Svetlana Andreevna
    Sapiev, Aslan Anzorovich
    Nametullaeva, Amiliya Poladovna
    Mezhidova, Esiat Abubakarovna
    Ragibov, Sarvar Sayd Ogly
    Khasanov, Murad Aslambekovich
    Adzhieva, Madina Elbrusovna
    Nazarova, Naida Khizrievna
    Ismailova, Maryam Muradovna
    Maslova, Alina Yurievna
    INTERNATIONAL TRANSACTION JOURNAL OF ENGINEERING MANAGEMENT & APPLIED SCIENCES & TECHNOLOGIES, 2022, 13 (08):
  • [35] Retinal Neurovascular Impairment in Non-diabetic and Non-dialytic Chronic Kidney Disease Patients
    Zeng, Xiaomin
    Hu, Yijun
    Chen, Yuanhan
    Lin, Zhanjie
    Liang, Yingying
    Liu, Baoyi
    Zhong, Pingting
    Xiao, Yu
    Li, Cong
    Wu, Guanrong
    Kong, Huiqian
    Du, Zijing
    Ren, Yun
    Fang, Ying
    Ye, Zhiming
    Yang, Xiaohong
    Yu, Honghua
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [36] Evaluation of Cardiovascular Status with Non-Invasive Markers in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease
    Karakose, Suleyman
    Guney, Ibrahim
    TURKISH JOURNAL OF NEPHROLOGY, 2020, 29 (03): : 221 - 225
  • [37] Aliskiren and losartan trial in non-diabetic chronic kidney disease
    Woo, Keng-Thye
    Choong, Hui-Lin
    Wong, Kok-Seng
    Tan, Han-Kim
    Foo, Marjorie
    Fook-Chong, Stephanie
    Lee, Evan J. C.
    Anantharaman, Vathsala
    Lee, Grace S. L.
    Chan, Choong-Meng
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2014, 15 (04) : 515 - 522
  • [38] Hepcidin: another culprit for complications in patients with chronic kidney disease?
    Nakanishi, Takeshi
    Hasuike, Yukiko
    Otaki, Yoshinaga
    Kida, Aritoshi
    Nonoguchi, Hiroshi
    Kuragano, Takahiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (10) : 3092 - 3100
  • [39] Use of vitamin D in chronic kidney disease patients
    Gal-Moscovici, Anca
    Sprague, Stuart M.
    KIDNEY INTERNATIONAL, 2010, 78 (02) : 146 - 151
  • [40] Vitamin D in Chronic Kidney Disease and Dialysis Patients
    Jean, Guillaume
    Souberbielle, Jean Claude
    Chazot, Charles
    NUTRIENTS, 2017, 9 (04)